Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?

Affected Ultragenyx Pharmaceutical Inc. Investor Summary

• Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: class="ticket-symbol" data-toggle="modal" href="#financial-modal">RARE )
• What: Securities fraud class action lawsuit filed
• Class Period: August 3, 2023, through December 26, 2025
• Deadline to Seek Lead Plaintiff Status: April 6, 2026
• Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's drug, setrusumab
• Investor Action: Contact Kessler Topaz Meltzer & Check, LLP () for recovery options at no cost to investor

RADNOR, Pa., Feb. 24, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP () informs investors that a securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (Ultragenyx) (NASDAQ: class="ticket-symbol" data-toggle="modal" href="#financial-modal">RARE ) on behalf of those who purchased or acquired Ultragenyx common stock between August 3, 2023, and December 26, 2025, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 (N.D. Cal.). Investors have until April 6, 2026, to file for lead plaintiff status.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Ultragenyx Pharmaceutical Inc. common stock and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at:

(484) 270-1453
[email protected]
or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

encourages Ultragenyx investors to contact the firm for more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit. The complaint in this matter was not filed by KTMC.

CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

MENAFN24022026003732001241ID1110785466